Baidu
map

Mirikizumab达到溃疡性结肠炎研究的主要终点

2021-03-18 Allan MedSci原创

溃疡性结肠炎(UC)是大肠的一种慢性疾病,常常使人衰弱,并影响全球数百万人。UC的症状可能包括血液和粘液引起的慢性腹泻、腹痛和绞痛以及体重减轻。UC可以对工作、家庭和社交活动产生重大影响。

溃疡性结肠炎(UC)是大肠的一种慢性疾病,常常使人衰弱,并影响全球数百万人。UC的症状可能包括血液和粘液引起的慢性腹泻、腹痛和绞痛以及体重减轻。UC可以对工作、家庭和社交活动产生重大影响。

礼来公司的抗IL-23p19单克隆抗体(mAb)mirikizumab在III期溃疡性结肠炎(UC)研究中达到了主要终点和所有关键的次要终点。为期12周的LUCENT-1诱导研究评估了mirikizumab治疗中重度UC患者的有效性和安全性。

在LUCENT-1试验中,与安慰剂相比,mirikizumab在第12周达到了临床缓解的主要终点。这意味着结肠的炎症得到控制或解决,导致症状正常化或接近正常化。此外,mirikizumab在第12周达到了所有主要次要终点,这包括减少肠急症、临床反应、内镜缓解、症状缓解和内镜组织学炎症的改善。

Mirikizumab还在开始治疗后的4周内就表现出患者症状的快速改善,并且减轻了先前对生物制剂或Janus激酶(JAK)抑制剂疗法无反应或已停止反应的患者的症状。

礼来公司免疫学发展副总裁Lotus Mallbris说:“患有UC的人们通常很难有效地控制这种疾病的复发。有了这些积极的结果,我们希望这项研究能够持续52周,以提供更多数据”。

 

原始出处:

http://www.pharmatimes.com/news/lillys_mirikizumab_hits_primary_endpoint_in_ulcerative_colitis_study_1365367

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-09-05 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-06-16 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2022-02-28 smallant2002
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-07-30 DR.Fu SIR

    值得学习和借鉴经验!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1695226, encodeId=76bf169522683, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sun Sep 05 03:31:36 CST 2021, time=2021-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912568, encodeId=4065191256829, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Jun 16 19:31:36 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930819, encodeId=0c08193081924, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon Feb 28 21:31:36 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003900, encodeId=d6d01003900a4, content=值得学习和借鉴经验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Fri Jul 30 15:22:04 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996989, encodeId=f5821996989a4, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sat Aug 07 10:31:36 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949876, encodeId=5b759498e623, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201019/b0de510014674ddc8cb5420827082bc0/27fbae1101bc40ff8ce56f8af41876a5.jpg, createdBy=cf015427221, createdName=Surgeon L, createdTime=Sun Mar 21 12:20:15 CST 2021, time=2021-03-21, status=1, ipAttribution=)]
    2021-03-21 Surgeon L

    666

    0

相关资讯

英夫利昔单抗对难治性溃疡性结肠炎的疗效“更佳”

圣迭戈(EGMN)——在医院医学会年会上,加州大学圣迭戈分校的胃肠病学家Derek R. Patel博士指出,英夫利昔单抗是重度急性激素难治性溃疡性结肠炎(UC)的最佳补救治疗。   在一项随机研究中,Laharie博士及其同事比较了56例接受英夫利昔单抗治疗的激素难治性UC患者和55例接受环孢菌素治疗的相似患者,结果显示各组1周内的有效率均约为85%。随访第3个月时,环孢菌素组和英

拓展阅读

Phytomedicine:加减交气散增强慢性溃疡性结肠炎上皮细胞自噬,抑制TNF触发的细胞凋亡

探讨加减交气散(Modified Jiaoqi Powder,MJQP)在慢性溃疡性结肠炎(UC)中的有利作用和潜在的分子机制。

UEGJ:非戈替尼和乌帕替尼治疗溃疡性结肠炎的实际疗效和安全性比较

乌帕替尼的短期疗效明显优于非戈替尼,而不良事件的发生频率更高,特别是在以前未接触过托法替尼治疗的患者中。因此,在选择乌帕替尼和非戈替尼之前,应优先考虑疗效或安全性。

溃疡性结肠炎合并持续性妊娠期恶心呕吐1例

39 岁 UC 患者拟备孕,有不良孕史。孕期经历 NVP、营养缺乏等,存在自行停药情况。经营养干预等,妊娠结局良好,产后 UC 复发。强调 IBD 合并妊娠管理重点及营养监测、治疗对母婴健康的重要性。

Baidu
map
Baidu
map
Baidu
map